CLEARBRIDGE HEALTH LIMITED
(Company Registration No.: 201001436C)
(Incorporated in the Republic of Singapore)

USE OF PROCEEDS FROM THE RIGHTS ISSUE

1. INTRODUCTION

1.1 The board of directors (the "**Board**" or "**Directors**") of Clearbridge Health Limited (the "**Company**", and together with its subsidiaries, referred to as the "**Group**") refers to the announcements of the Company dated 27 September 2024, 7 October 2024, 16 October 2024, 23 October 2024, 28 October 2024, 7 November 2024, 19 November 2024, 20 November 2024, 22 November 2024, 9 December 2024 and 11 December 2024 in relation to the renounceable non-underwritten rights issue of 1,239,482,704 new ordinary shares in the capital of the Company (the "**Rights Issue**") (collectively, the "**Rights Issue Announcements**").

1.2 Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Rights Issue Announcements.

2. USE OF PROCEEDS FROM THE RIGHTS ISSUE

2.1 Pursuant to the completion of the Rights Issue, the Company raised the Final Net Proceeds amounting to approximately S$2.229 million, after deducting expenses of approximately S$250,000 incurred in connection with the Rights Issue.

2.2 The Company wishes to provide an update on the use of the Final Net Proceeds as follows:

Use of the Final Net Proceeds	**Allocation of the Final Net Proceeds (S$'000)**	**Amount utilised as at the date of this announcement (S$'000)**	**Balance of the Final Net Proceeds as at the date of this announcement (S$'000)**
General working capital requirements of the Group	2,229	772 (1)	1,457

Note:

(1) A breakdown of the amount utilised for the general working capital requirements of the Group is as follows:

Description	**Amount Utilised (S$'000)**
Payments for payroll-related expenses and Directors' fees	405
Payments to suppliers	139
Payments for loan principal and interests	134
Payments for professional fees	25
Rental Expenses	15

Description	Amount Utilised (S$'000)
Others	54
Total	772

2.3 The use of the Final Net Proceeds disclosed above is in accordance with the intended use of proceeds as disclosed in the Rights Issue Announcements. The Board will continue to make periodic announcements on the utilisation of the Final Net Proceeds as and when such proceeds are materially disbursed or utilised, and whether such use is in accordance with the stated use of proceeds. The Company will also provide a status report on the use of the Final Net Proceeds in its annual report(s) and financial results announcement(s), until such time as the Final Net Proceeds have been fully utilised.

By Order of the Board

Yee Pinh Jeremy
Executive Director and Chief Executive Officer

13 January 2025

---

*This announcement has been reviewed by the Company's sponsor, ZICO Capital Pte. Ltd. (the "**Sponsor**").*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Goh Mei Xian, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.